Key result
Intravenous indomethacin achieves complete PDA closure in a full-term infant, lowering cardiothoracic ratio ~16 points.
Why the study?
Intravenous indomethacin is administered for patent ductus arteriosus mainly in preterm infants, whereas its effectiveness in full-term infants with patent ductus arteriosus remains undetermined.
Case Report (n=1)
No
Indomethacin may be a useful therapy for symptomatic patent ductus arteriosus in full-term infants.
Answers are grounded in this paper and cite their sources.
May support indomethacin for symptomatic full-term PDA; leaves open need for controlled trials before practice change.
•Full-term infants have mature DA closure mechanisms.•Premature infants show delayed lung metabolism of prostaglandin.•IND may be a useful therapy for PDA.
No takes yet. Share an insight, caveat, or question.
Tanabe et al. (2019) conducted a case report in Symptomatic Patent Ductus Arteriosus (PDA) (n=1). Intravenous indomethacin (IND) was evaluated on Complete closure of the patent ductus arteriosus without surgical intervention. Intravenous indomethacin (4 doses total) reduced a 6 mm patent ductus arteriosus to complete closure and lowered cardiothoracic ratio from 67% to 51% at 1 month in a 12-day-old full-term infant.
Synapse has enriched 10 related papers. Consider them for comparative context: